Literature DB >> 1630313

Human neutrophil response to recombinant neisserial Opa proteins.

R J Belland1, T Chen, J Swanson, S H Fischer.   

Abstract

Interactions of human neutrophils with recombinant Escherichia coli expressing gonococcal outer membrane Opa proteins were examined using chemiluminescent and biological assays. Seven opa loci from Neisseria gonorrhoeae MS11 4.8 were expressed as beta-lactamase-Opa fusion proteins that contained all but the mature N-terminal amino acid of the full-length Opa protein fused to three N-terminal amino acids derived from the mature beta-lactamase. The Opa fusion proteins were exported and assembled in the outer membrane of E. coli in a manner similar to that of Opa in N. gonorrhoeae, as evaluated by antibody binding and in situ proteolytic cleavage. All fusion proteins exhibited the characteristic heat-modifiable migration in SDS-polyacrylamide gel electrophoresis that typifies Opa proteins of neisseriae. Opa fusion proteins conferred on E. coli the ability to stimulate a chemiluminescent response from human neutrophils in the absence of antibody or complement. The nature of the response in terms of chemiluminescence, phagocytosis, and killing was in all cases analogous to that seen using N. gonorrhoeae expressing the equivalent Opa protein. Neither E. coli nor gonococci expressing OpaA elicited a response from neutrophils. Use of E. coli expressing Opa fusions should be useful in defining their biological activities and pathogenic roles.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1630313     DOI: 10.1111/j.1365-2958.1992.tb01345.x

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  28 in total

Review 1.  Negative signaling in health and disease.

Authors:  K M Coggeshall
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  Neisseria gonorrhoeae porin modifies the oxidative burst of human professional phagocytes.

Authors:  D R Lorenzen; D Günther; J Pandit; T Rudel; E Brandt; T F Meyer
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

3.  In vivo selection for Neisseria gonorrhoeae opacity protein expression in the absence of human carcinoembryonic antigen cell adhesion molecules.

Authors:  Amy N Simms; Ann E Jerse
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

Review 4.  A bacterial siren song: intimate interactions between Neisseria and neutrophils.

Authors:  Alison K Criss; H Steven Seifert
Journal:  Nat Rev Microbiol       Date:  2012-01-31       Impact factor: 60.633

5.  Defining the roles of human carcinoembryonic antigen-related cellular adhesion molecules during neutrophil responses to Neisseria gonorrhoeae.

Authors:  Helen Sarantis; Scott D Gray-Owen
Journal:  Infect Immun       Date:  2011-11-07       Impact factor: 3.441

6.  Alpha-2,3-sialyltransferase enhances Neisseria gonorrhoeae survival during experimental murine genital tract infection.

Authors:  Hong Wu; Ann E Jerse
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

7.  Differential response of human monocytes to Neisseria gonorrhoeae variants expressing pili and opacity proteins.

Authors:  B Knepper; I Heuer; T F Meyer; J P van Putten
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

8.  An in vitro-differentiated human cell line as a model system to study the interaction of Neisseria gonorrhoeae with phagocytic cells.

Authors:  C R Hauck; D Lorenzen; J Saas; T F Meyer
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

Review 9.  Rho GTPases as pathogen targets: Focus on curable sexually transmitted infections.

Authors:  Cristián A Quintero; Julián Gambarte Tudela; María T Damiani
Journal:  Small GTPases       Date:  2015-05-29

10.  Expression of sialyltransferase is not required for interaction of Neisseria gonorrhoeae with human epithelial cells and human neutrophils.

Authors:  D J McGee; G C Chen; R F Rest
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.